Research programme: adenovector-based therapeutics and vaccines - GenVec/Washington University at St. Louis

Drug Profile

Research programme: adenovector-based therapeutics and vaccines - GenVec/Washington University at St. Louis

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator GenVec; Washington University
  • Developer GenVec
  • Class Antibodies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Haemophilia

Most Recent Events

  • 05 Jan 2017 GenVec enters into an option agreement with Washington University to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting
  • 03 Jul 2015 Early research in Haemophilia indication in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top